Cargando…

Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia

Detalles Bibliográficos
Autores principales:	Chauvineau-Grenier, Angélique, Bastard, Paul, Casanova, Jean-Laurent, Rossi, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177133/ https://www.ncbi.nlm.nih.gov/pubmed/35676568 http://dx.doi.org/10.1007/s10875-022-01295-5

Ejemplares similares

Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2021)

Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2022)

Low Lymphocytes and IFN-Neutralizing Autoantibodies as Biomarkers of COVID-19 Mortality
por: Troya, Jesús, et al.
Publicado: (2022)

Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma
por: Vazquez, Sara E., et al.
Publicado: (2021)

Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain
por: Troya, Jesús, et al.
Publicado: (2021)

No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients
por: Philippot, Quentin, et al.
Publicado: (2023)

Interferon-β Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2
por: Bastard, Paul, et al.
Publicado: (2021)

Human autoantibodies underlying infectious diseases
por: Puel, Anne, et al.
Publicado: (2022)

Neutralizing Type I Interferon Autoantibodies in Japanese Patients With Severe COVID-19
por: Eto, Shohei, et al.
Publicado: (2022)

Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia
por: Philippot, Quentin, et al.
Publicado: (2023)

Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19
por: Eto, Shohei, et al.
Publicado: (2022)

Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients
por: Koning, Rutger, et al.
Publicado: (2021)

Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia
por: de Prost, Nicolas, et al.
Publicado: (2021)

INF-α and Ototoxicity
por: Sharifian, Mohammad Reza, et al.
Publicado: (2013)

Autoantibodies against type I IFNs in patients with critical influenza pneumonia
por: Zhang, Qian, et al.
Publicado: (2022)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
por: Zielecki, Piotr, et al.
Publicado: (2020)

High-flow nasal oxygen in severe COVID-19 pneumonia and tocilizumab
por: Mandal, M., et al.
Publicado: (2022)

Testing the efficacy of tocilizumab in patients with COVID-19 pneumonia
por: Agirbasli, Mehmet, et al.
Publicado: (2021)

Autoantibodies Against Type I IFNs in Patients with Ph-Negative Myeloproliferative Neoplasms
por: Borsani, Oscar, et al.
Publicado: (2021)

Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients
por: Gervais, Adrian, et al.
Publicado: (2023)

Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms
por: Borsani, Oscar, et al.
Publicado: (2022)

Neutralizing Anti-interferon-γ Autoantibodies: an Ameliorating Factor in COVID-19 Infection?
por: Kacar, Mark, et al.
Publicado: (2021)

Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona
por: Solanich, Xavier, et al.
Publicado: (2021)

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia
por: Shinomiya, Shohei, et al.
Publicado: (2021)

Effects of the novel formin INF1 on ciliogenesis
por: Copeland, S, et al.
Publicado: (2015)

Anti-GM-CSF Neutralizing Autoantibodies in Colombian Patients with Disseminated Cryptococcosis
por: Arango-Franco, Carlos A., et al.
Publicado: (2023)

Nanostructured Self-Assembly of Inverted Formin 2 (INF2) and F-Actin–INF2 Complexes Revealed by Atomic Force Microscopy
por: Sharma, Shivani, et al.
Publicado: (2014)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
por: Salama, Carlos, et al.
Publicado: (2020)

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1
por: Bastard, Paul, et al.
Publicado: (2021)

Statistical models to predict clinical outcomes with anakinra vs. tocilizumab treatments for severe pneumonia in COVID19 patients
por: Piconi, Stefania, et al.
Publicado: (2023)

IKKepsilon involvement in Tax-mediated activation of INF pathway
por: Cremonese, Giorgia, et al.
Publicado: (2011)

Pulmonary Artery Pseudoaneurysm Secondary to Lung Inf lammation
por: Ishimoto, Shinichirou, et al.
Publicado: (2018)

INF-01 Les Isolements : Actualites Et Perspectives
Publicado: (2005)

INfORM: Inference of NetwOrk Response Modules
por: Marwah, Veer Singh, et al.
Publicado: (2018)

Exogenous dsRNA-Induced Silencing of the Phytophthora infestans Elicitin Genes inf1 and inf4 Suppresses Its Pathogenicity on Potato Plants
por: Ivanov, Artemii A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n582o793ldj8jq3k3j0e7q9di6